[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Hazan EJ, Hornicek FJ, Tomford W, Gebhardt MC, Mankin HJ: The effect of adjuvant chemotherapy on osteoarticular allografts. Clin Orthop Relat Res; 2001 Apr;(385):176-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of adjuvant chemotherapy on osteoarticular allografts.
  • Two hundred lower extremity osteoarticular allografts (in 200 patients) performed for aggressive or malignant bone tumors between 1976 and 1997 included 124 grafts of the distal femur, 46 of the proximal tibia, and 30 of the proximal femur.
  • Seventy-four patients did not receive chemotherapy, and 126 received either adjuvant or neoadjuvant therapy.
  • The diagnoses, mean ages, and length of followup were different for the two groups because most of the patients in the chemotherapy group had osteosarcoma, whereas the largest number in the control group had chondrosarcoma or parosteal osteosarcoma.
  • The extent of the surgery was essentially the same for both patient groups, as is reflected by a low recurrence rate (7% for the control and 6% for the chemotherapy group).
  • A statistical comparison of the various parameters showed that the infection, fracture, and amputation rates were the same, but the nonunion rate was markedly increased in the patients who received chemotherapy (32% versus 12%).
  • Cox regression and Kaplan-Meier studies showed that chemotherapy had a significant effect on outcome, with the success rates for the two groups being quite different (72% versus 56%).
  • The results for the distal femur showed a greater effect than for either the proximal tibia or the proximal femur.
  • Analysis of these data suggest the distal femur is perhaps the most prone to healing problems, possibly based in part on the extent of the surgery.
  • A final study supports the concept that the results improved in later years, suggesting a modification or application of the drugs used, better selection of patients, and improvements in surgical technique.
  • [MeSH-major] Bone Neoplasms / surgery. Bone Transplantation. Chondrosarcoma / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Child. Female. Femur / transplantation. Humans. Male. Middle Aged. Reconstructive Surgical Procedures. Tibia / transplantation. Transplantation, Homologous

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11302311.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Sabo D, Bernd L, Buchner M, Treiber M, Wannenmacher M, Ewerbeck V, Parsch D: [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors]. Orthopade; 2003 Nov;32(11):1003-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intraoperative extracorporeal irradiation and replantation in local treatment of primary malignant bone tumors].
  • In 13 patients with primary malignant bone tumors (10 Ewing's sarcoma, 1 parosteal osteosarcoma, 1 adamantinoma recurrence, and 1 MFH) local therapy was performed as intraoperative extracorporeal irradiation and replantation (IEIR) of the involved bone segment (5 tibia, 2 femur, and 6 pelvis).
  • Of the 13 patients (69%), 9 are alive at the time of the follow-up (5 CDF, 4 AWM(treated)) and 4 patients died of disease (DOD).
  • Up to now during the follow-up of 32 months (6-57), no local recurrence was observed in the replanted bone segments.
  • In cases of mechanical failure, the replanted segment could mostly be preserved by surgical revision and autologous bone grafting.
  • IEIR must be seen as an extraordinary reconstruction procedure in cases where established procedures such as endoprosthesis, biological reconstructions, or rotationplasties cannot be used or are refused by the patient.
  • [MeSH-major] Amputation / methods. Bone Neoplasms / radiotherapy. Bone Neoplasms / surgery. Brachytherapy / methods. Limb Salvage / methods. Replantation / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Ameloblastoma / drug therapy. Ameloblastoma / pathology. Ameloblastoma / radiotherapy. Ameloblastoma / surgery. Child, Preschool. Combined Modality Therapy. Female. Femoral Neoplasms / drug therapy. Femoral Neoplasms / pathology. Femoral Neoplasms / radiotherapy. Femoral Neoplasms / surgery. Follow-Up Studies. Histiocytic Sarcoma / drug therapy. Histiocytic Sarcoma / pathology. Histiocytic Sarcoma / radiotherapy. Histiocytic Sarcoma / surgery. Humans. Male. Neoadjuvant Therapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Osteosarcoma / radiotherapy. Osteosarcoma / surgery. Radiotherapy Dosage. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / pathology. Sarcoma, Ewing / radiotherapy. Sarcoma, Ewing / surgery. Tibia / pathology. Tibia / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Klin Padiatr. 1988 May-Jun;200(3):243-52 [3145357.001]
  • [Cites] J Bone Joint Surg Am. 1987 Apr;69(4):583-95 [2952660.001]
  • [Cites] Orthop Clin North Am. 1987 Apr;18(2):275-89 [3550576.001]
  • [Cites] Langenbecks Arch Surg. 2003 Jan;387(9-10):355-65 [12536331.001]
  • [Cites] Acta Orthop Scand. 1996 Dec;67(6):583-8 [9065072.001]
  • [Cites] Cancer. 1982 Aug 15;50(4):613-30 [7046906.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3685-90 [12552977.001]
  • [Cites] J Bone Joint Surg Am. 1995 Jan;77(1):54-64 [7822356.001]
  • [Cites] Cancer. 1976 Jan;37(1):1-11 [1082364.001]
  • [Cites] Z Orthop Ihre Grenzgeb. 1992 Jul-Aug;130(4):285-9 [1413973.001]
  • [Cites] J Bone Joint Surg Br. 1988 May;70(3):348-53 [3163694.001]
  • [Cites] J Orthop Res. 1985;3(4):389-404 [3906062.001]
  • [Cites] Cancer. 1983 Sep 15;52(6):1017-21 [6883269.001]
  • [Cites] Unfallchirurg. 1999 Jul;102(7):580-8 [10459306.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):223-30 [1884544.001]
  • [Cites] Int Orthop. 1998;22(1):32-6 [9580457.001]
  • [Cites] Int Orthop. 1997;21(5):283-90 [9476156.001]
  • [Cites] Acta Orthop Scand. 1988 Feb;59(1):34-8 [3128053.001]
  • [Cites] J Bone Joint Surg Br. 2000 Mar;82(2):276-82 [10755441.001]
  • [Cites] J Bone Joint Surg Am. 1986 Mar;68(3):362-9 [3456348.001]
  • [Cites] J Bone Joint Surg Am. 1991 Sep;73(8):1123-42 [1890115.001]
  • [Cites] Clin Orthop Relat Res. 1993 Jan;(286):241-6 [8425352.001]
  • [Cites] Clin Orthop Relat Res. 1999 Nov;(368):196-206 [10613169.001]
  • [Cites] Clin Orthop Relat Res. 1993 Oct;(295):226-38 [8403653.001]
  • [Cites] Clin Orthop Relat Res. 1990 Feb;(251):249-53 [2295182.001]
  • [Cites] Rev Chir Orthop Reparatrice Appar Mot. 1991;77(1):6-13 [1829244.001]
  • (PMID = 14615850.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopade
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


3. Wines A, Bonar F, Lam P, McCarthy S, Stalley P: Telangiectatic dedifferentiation of a parosteal osteosarcoma. Skeletal Radiol; 2000 Oct;29(10):597-600
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telangiectatic dedifferentiation of a parosteal osteosarcoma.
  • A unique case of parosteal osteosarcoma (POS) of the proximal femur, with areas of telangiectatic dedifferentiation, in a 28-year-old woman is reported.
  • A biopsy diagnosis of POS was established.
  • The patient was treated with two cycles of intraarterial chemotherapy, followed by limb salvage surgery.
  • Histological examination of the resected specimen showed POS with areas of dedifferentiation composed of highgrade telangiectatic osteosarcoma with associated secondary aneurysmal bone cyst change.
  • [MeSH-major] Femoral Neoplasms / diagnosis. Osteosarcoma, Juxtacortical / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Cysts, Aneurysmal / diagnosis. Female. Femur / pathology. Humans. Infusions, Intra-Arterial. Magnetic Resonance Imaging. Osteosarcoma / diagnosis

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11127684.001).
  • [ISSN] 0364-2348
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 13
  •  go-up   go-down


Advertisement
4. Goto T, Okuma T, Nakada I, Hozumi T, Kondo T: [Preoperative adjuvant therapy for primary malignant bone tumors]. Gan To Kagaku Ryoho; 2007 Nov;34(11):1750-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Preoperative adjuvant therapy for primary malignant bone tumors].
  • In primary bone sarcomas, the efficacy of chemotherapy varies according to the histological types.
  • Prognoses are poor in patients with osteosarcoma or Ewing's sarcoma, when surgery alone is performed.
  • However, because these sarcomas are chemosensitive, their prognoses have been improved with adjuvant chemotherapy.
  • Nowadays, in highgrade bone sarcomas, especially in osteosarcoma, Ewing.s sarcoma and malignant fibrous histiocytoma of bone, adjuvant chemotherapy including neoadjuvant or preoperative chemotherapy is usually performed.
  • The purpose of the neoadjuvant chemotherapy is (I) to prevent distant metastases, (II) to reduce the size of the primary tumor and (III) to evaluate the efficacy of the chemotherapeutic agents.
  • Reducing the tumor size facilitates easier excision with less risk of local recurrence.
  • Evaluating the efficacy of the chemotherapeutic agents in preoperative chemotherapy facilitates rational selection of postoperative chemotherapeutic agents.
  • Commonly used drugs include adriamycin, ifosfamide, cisplatin, methotrexate and vincristine in osteosarcoma, and vincristine, adriamycin, cyclophosphamide, ifosfamide, actinomycin-D and etoposide in Ewing's sarcoma.
  • In contrast, chondrosarcomas are chemoresistant, and chemotherapy is rarely performed.
  • Low-grade bone sarcomas, e. g., parosteal osteosarcoma, central low-grade osteosarcoma, are well cured only by surgical excision, and adjuvant chemotherapy is not performed for these low-grade sarcomas.
  • To enhance the efficacy of preoperative chemotherapy, various modalities have been used e. g., intraarterial infusion, caffeine-assisted chemotherapy, and local perfusion with hyperthermia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy
  • [MeSH-minor] Cyclophosphamide / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Neoadjuvant Therapy. Neoplasm Metastasis / prevention & control. Osteosarcoma / drug therapy. Osteosarcoma / surgery. Prognosis. Sarcoma, Ewing / drug therapy. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / drug therapy. Soft Tissue Neoplasms / surgery. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030009.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; UM20QQM95Y / Ifosfamide; VAC protocol; VACA protocol; VAIA protocol
  •  go-up   go-down


5. Kilpatrick SE, Geisinger KR, King TS, Sciarrotta J, Ward WG, Gold SH, Bos GD: Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma. Mod Pathol; 2001 Dec;14(12):1277-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of HER-2/neu immunoexpression among various histologic subtypes and grades of osteosarcoma.
  • Overexpression of the HER-2/neu oncogene appears to have prognostic significance in breast cancer.
  • Recently, some have reported a relationship between increased immunohistochemical expression in osteosarcoma and poor clinical outcome.
  • Despite limited data, a pilot trial of Herceptin, which targets the oncogene product, has been initiated for the therapy of some metastatic osteosarcomas (CCG-P9852).
  • Archival formalin-fixed, paraffin-embedded tissue obtained from 41 patients diagnosed with osteosarcoma was examined immunohistochemically by 2 antibodies against the HER-2/neu oncogene product: CB-11 (monoclonal, 1/100) and Oncor (polyclonal, 1/200).
  • All but one tumor (case of recurrent dedifferentiated parosteal osteosarcoma) represented primary tumor samples; when applicable, only prechemotherapy biopsies were analyzed.
  • The study sample included the full spectrum of histologic subtypes and grades of osteosarcoma (25 conventional high grade; 3 telangiectatic; 1 small cell; 6 parosteal; 1 periosteal; and 5 low-grade intramedullary).
  • A case of metastatic breast cancer with known overexpression of the HER-2/neu oncogene served as the positive control.
  • Complete membranous positivity, considered prognostically significant in breast cancer, was not seen in any of our osteosarcoma cases.
  • At least focal cytoplasmic positivity was documented in 40 (98%) tumors using the CB11 antibody and in 34 (83%) using the Oncor antibody.
  • The intensity of the cytoplasmic staining (0, 1-3+) did not correlate with histologic subtype/grade, response to chemotherapy (<90% versus > or = 90% necrosis), metastasis, or survival.
  • Immunohistochemical overexpression of the HER-2/neu oncogene, defined as complete membranous positivity, is not present in our series of osteosarcomas.
  • Cytoplasmic positivity is observed in most osteosarcomas, irrespective of histologic subtype/grade, and is not associated with response to preoperative chemotherapy or disease progression.
  • [MeSH-major] Bone Neoplasms / metabolism. Osteosarcoma / metabolism. Receptor, ErbB-2 / biosynthesis


6. Asavamongkolkul A, Waikakul S, Phimolsarnti R, Kiatisevi P, Wangsaturaka P: Endoprosthetic reconstruction for malignant bone and soft-tissue tumors. J Med Assoc Thai; 2007 Apr;90(4):706-17
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoprosthetic reconstruction for malignant bone and soft-tissue tumors.
  • BACKGROUND: Nowadays, the results of the management of malignant bone and soft-tissue tumors have been dramatically improved because of the advance in imaging, chemotherapy, radiation therapy, and surgical techniques.
  • Patients can have longer survival times with limb-salvage surgery.
  • Several techniques of reconstruction have been advocated and gained more popularity following malignant tumor resection by using allograft, tumor prostheses, composite allograft prosthesis, or arthrodesis.
  • OBJECTIVE: To report the preliminary results of 32 endoprosthetic reconstructions following malignant bone and soft-tissue tumor resection.
  • MATERIAL AND METHOD: Since September 1988, the authors have performed 188 limb-salvage surgical operations for the treatment of musculoskeletal tumors at Siriraj Hospital.
  • From March 1994 to July 2006, 32 endoprosthetic reconstructions were performed on 30 patients following malignant bone or soft-tissue tumor removal.
  • There were 16 males and 14 females with a mean age of 28 years (range 10-73).
  • The diagnosis was conventional osteosarcoma in 16 patients, parosteal osteosarcoma in two patients, chondrosarcoma in two patients, leiomyosarcoma in two patients, failed allograft in two patients and one patient each of periosteal osteosarcoma, Ewing's sarcoma, Gorham's disease, synovial sarcoma, malignant fibrous histiocytoma, metastatic renal cell carcinoma, and prosthetic loosening.
  • Wide excision was performed with a mean length of 18.5 cm (range 10-41).
  • Five proximal femurs, 17 distal femurs, 1 total femur 3 proximal tibias, 1 intercalary tibia, 4 proximal humerus and 1 distal humerus were used for reconstruction.
  • RESULTS: The mean follow-up time was 26 months (range 6-128.7).
  • Sixteen patients are continuously free of the disease, two are alive with the disease, two had no evidence of the disease, nine died of the disease, and one patient died from complication of hypertension.
  • The mean Musculoskeletal Tumor Society functional analysis for upper extremity reconstruction was 93% (range 86.7-100) and for lower extremity was 89% (range 63.3-100).
  • CONCLUSION: Endoprosthetic reconstruction could yield satisfactory results as a wide excision and limb-salvage for patients with malignant bone and soft-tissue tumors.
  • [MeSH-major] Bone Neoplasms / surgery. Limb Salvage. Osteosarcoma / surgery. Sarcoma, Ewing / surgery. Soft Tissue Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17487125.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


7. Futani H, Okayama A, Maruo S, Kinoshita G, Ishikura R: The role of imaging modalities in the diagnosis of primary dedifferentiated parosteal osteosarcoma. J Orthop Sci; 2001;6(3):290-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of imaging modalities in the diagnosis of primary dedifferentiated parosteal osteosarcoma.
  • Dedifferentiated parosteal osteosarcoma (dd-POS) is defined as high-grade sarcomatous components coexisting with low-grade POS components.
  • With regard to the histological diagnosis of dd-POS, the sampling of a small area of dedifferentiation through the densely mineralized POS can be a problem.
  • We report a patient in whom dedifferentiation was shown by computed tomography (CT) and magnetic resonance imaging (MRI).
  • Neoadjuvant chemotherapy was administered, followed by wide resection and adjuvant chemotherapy.
  • Four years after the surgery, partial lobulectomy was required because of a pulmonary metastasis.
  • Based on the initial diagnosis and, consequently, the optimal treatment of combined chemotherapy and wide resection, our patient showed a good clinical outcome.
  • [MeSH-major] Bone Neoplasms / diagnosis. Bone Neoplasms / pathology. Diagnostic Imaging. Fibula. Osteosarcoma, Juxtacortical / diagnosis. Osteosarcoma, Juxtacortical / pathology
  • [MeSH-minor] Adult. Chemotherapy, Adjuvant. Gadolinium. Humans. Image Enhancement. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed


8. Bertoni F, Bacchini P, Staals EL, Davidovitz P: Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute. Cancer; 2005 Jun 1;103(11):2373-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dedifferentiated parosteal osteosarcoma: the experience of the Rizzoli Institute.
  • BACKGROUND: Dedifferentiated parosteal osteosarcoma (DPOS) is a variant of osteosarcoma in which a high-grade sarcoma coexists with a conventional parosteal osteosarcoma (c-POS), either at presentation (synchronous type) or at the time of recurrence (metachronous type).
  • The objective of this study was to analyze the clinicopathologic and radiographic features of a relatively large number of patients with DPOS in an attempt to define further the histologic and biologic behavior of this rare entity.
  • METHODS: In a series of 120 patients with parosteal osteosarcoma who were seen at the Rizzoli Institute from 1958 to 2000, the authors identified 29 patients who were diagnosed with DPOS.
  • The authors reviewed the clinical and radiologic features, histologic sections, treatments, and outcomes in this group of patients with DPOS.
  • One tumor involved the scapula, one involved the ilium, and another involved the skull.
  • All 26 of the other tumors were located in the long bones (14 in the femur, 5 in the humerus, 3 in the tibia, 3 in the fibula, and 1 in the ulna).
  • Histologically, the dedifferentiated component was high-grade osteoblastic osteosarcoma in 14 patients, fibroblastic osteosarcoma in 10 patients, giant cell-rich osteosarcoma in 3 patients, and chondroblastic osteosarcoma in 2 patients.
  • All tumors were Stage IIB, and invasion of the medullary canal was detected in 19 patients (65%).
  • Twenty-eight patients underwent surgery, and 18 of those patients received chemotherapy (5 patients received neoadjuvant chemotherapy, and 13 patients received adjuvant).
  • Of the nine patients who died, one patient received no treatment, five patients underwent surgery (with three patients achieving adequate margins) in combination with chemotherapy, and three patients underwent surgery only (with adequate margins achieved).
  • Of the 20 patients who remained alive, 13 patients underwent surgery (with 10 patients achieving adequate margins) in combination with chemotherapy, whereas 7 patients underwent surgery only (all with adequate margins).
  • One patient died of causes unrelated to the tumor, and another patient died shortly after undergoing resection of a lesion in the skull.
  • [MeSH-major] Bone Neoplasms / pathology. Cell Differentiation. Osteosarcoma, Juxtacortical / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Survival Rate. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15852358.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


9. Kido A, Schneider-Stock R, Hauptmann K, Roessner A: Telomerase activity in juxtacortical and conventional high-grade osteosarcomas: correlation with grade, proliferative activity and clinical response to chemotherapy. Cancer Lett; 2003 Jun 30;196(1):109-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in juxtacortical and conventional high-grade osteosarcomas: correlation with grade, proliferative activity and clinical response to chemotherapy.
  • Seven samples from seven patients with juxtacortical osteosarcomas, and 27 samples from 19 patients with conventional high-grade osteosarcomas were investigated for a possible correlation between telomerase activity and clinicopathological features such as age, sex, and response to chemotherapy.
  • Of seven juxtacortical osteosarcomas, telomerase activity was weakly positive in three parosteal osteosarcomas, and highly positive in one parosteal osteosarcoma.
  • In contrast, of 27 conventional high-grade osteosarcomas, telomerase activity was weakly positive in eight tumors and highly positive in three.
  • Of all samples, 44.1% of the osteosarcomas showed telomerase activity (57.1% of juxtacortical and 40.7% of conventional osteosarcomas).
  • The majority of poor responders to chemotherapy showed no telomerase activity (nine of 11), whereas five of seven good responders showed strong or weak telomerase activity.
  • There was a significant correlation between telomerase activity and the response to chemotherapy (P<0.05).
  • Telomerase activity was not correlated with MIB-1 proliferation index, age at the time of surgery, or sex.
  • These findings suggest that telomerase activation occurs early in the oncogenesis of osteoblastic tumors without having an effect on the progression of these tumors.
  • In malignant osteoblastic tumors, the biological significance of telomerase activation is different from that described for most epithelial cancers.
  • [MeSH-major] Bone Neoplasms / enzymology. Osteosarcoma / enzymology. Osteosarcoma, Juxtacortical / drug therapy. Osteosarcoma, Juxtacortical / enzymology. Telomerase / metabolism

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12860297.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] EC 2.7.7.49 / Telomerase
  •  go-up   go-down


10. Hoshi M, Matsumoto S, Manabe J, Tanizawa T, Shigemitsu T, Takeuchi K, Kawaguchi N: Report of four cases with high-grade surface osteosarcoma. Jpn J Clin Oncol; 2006 Mar;36(3):180-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Report of four cases with high-grade surface osteosarcoma.
  • High-grade surface osteosarcoma is the rarest of the three types of surface osteosarcoma.
  • Four cases with high-grade surface osteosarcoma arising from the distal femur and tibia are reported in this study.
  • Radiologically, three cases presented characteristic appearances suggesting high-grade bone-forming sarcoma arising from the bone surface; however, one case was similar to other juxtacortical lesions such as periosteal and parosteal osteosarcoma, which typically have a better prognosis than high-grade surface osteosarcoma.
  • Therefore, all cases underwent biopsy to determine a definitive diagnosis.
  • Our strategy of treatment for high-grade surface osteosarcoma was a combination of wide resection and pre-/post-operative chemotherapy, equivalent to the treatment for conventional intramedullary osteosarcoma.
  • At the last follow-up, two cases were still undergoing chemotherapy, one case was continuously disease free during the follow-up period of 81 months, and one patient was living with no evidence of disease 60 months after surgery.
  • The aim of this study is to report the clinical information, oncological outcome and appropriate treatment for high-grade surface osteosarcoma.
  • [MeSH-major] Bone Neoplasms / surgery. Femoral Neoplasms / surgery. Osteosarcoma / surgery
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Male. Tibia / surgery. Tomography, X-Ray Computed. Treatment Outcome. Turner Syndrome / complications

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16533804.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Kaste SC, Fuller CE, Saharia A, Neel MD, Rao BN, Daw NC: Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features. Pediatr Blood Cancer; 2006 Aug;47(2):152-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric surface osteosarcoma: clinical, pathologic, and radiologic features.
  • BACKGROUND: Osteosarcoma (OS) arising from the surface of bone is far less common than its intramedullary counterpart.
  • PROCEDURE: We reviewed the clinical, radiographic, and pathologic features of 14 cases of pediatric surface OS treated at St. Jude Children's Research Hospital between 1970 and 2003.
  • RESULTS: Seven patients had parosteal, five had periosteal, and two had high-grade surface OS.
  • The median age at diagnosis was 16.2 years (range, 13.6-18.5 years).
  • None had metastatic disease at diagnosis.
  • Primary tumor sites included distal femur (n = 6), mid to proximal femur (n = 4), and mid to proximal tibia (n = 4).
  • All 14 patients were treated with surgery, and 7 (1 with parosteal, 4 with periosteal, 2 with high-grade tumors) received chemotherapy.
  • One patient experienced pulmonary metastasis of periosteal OS 16 months and 43 months after diagnosis; long-term disease-free survival followed resection of the metastatic tumors.
  • Twelve patients remained alive and disease-free a median of 10 years (range, 1.5-25.4 years) after diagnosis.
  • One patient died of high-grade surface OS 1.8 years after diagnosis, and one patient with periosteal OS died of gastric cancer 18.2 years after diagnosis of OS.
  • Complete resection is the treatment of choice regardless of tumor subtype.
  • Whereas chemotherapy is not indicated for parosteal OS, its role in periosteal OS remains controversial.
  • [MeSH-major] Bone Neoplasms / pathology. Osteosarcoma, Juxtacortical / pathology
  • [MeSH-minor] Adolescent. Female. Humans. Magnetic Resonance Imaging. Male. Retrospective Studies. Survival Analysis. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16123997.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-23099
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Bernd L, Saleh H, Zahlten-Hinguranage A, Zeifang F: [Parosteal osteosarcoma (POS). Clinical and therapeutic aspects]. Orthopade; 2002 Nov;31(11):1067-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Parosteal osteosarcoma (POS). Clinical and therapeutic aspects].
  • [Transliterated title] Das parossale Osteosarkom Klinische und therapeutische Aspekte.
  • Parosteal osteosarcoma is a malignant bone-forming tumor, which is characterized by its superficial origin and its high structural differentiation.
  • Because of the radiological and histological variability, finding the right diagnosis is a great challenge for physicians, radiologists, and pathologists, especially at the time of primary manifestation.
  • Often a benign tumor is imitated so that finding the correct diagnosis is indispensable.
  • Wide resection with sufficient margin is the adequate therapy.
  • High-grade parosteal osteosarcoma needs adjuvant chemotherapy.
  • Our own experience with secondary dedifferentiation and the possibility of primary undergrading shows that regarding diagnostics, operative therapy, and follow-up parosteal osteosarcoma should be treated like conventional osteosarcoma.
  • [MeSH-major] Bone Neoplasms. Femoral Neoplasms. Humerus. Osteosarcoma, Juxtacortical. Tibia
  • [MeSH-minor] Adolescent. Adult. Bone Transplantation. Female. Follow-Up Studies. Fracture Fixation, Internal. Humans. Male. Middle Aged. Prostheses and Implants. Time Factors

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12436325.001).
  • [ISSN] 0085-4530
  • [Journal-full-title] Der Orthopäde
  • [ISO-abbreviation] Orthopade
  • [Language] ger
  • [Publication-type] Case Reports; Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


13. Donaldson ME, Geist JR, Daley TD: Osteosarcoma of the jaws in children. Int J Paediatr Dent; 2004 Jan;14(1):54-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteosarcoma of the jaws in children.
  • Two cases of osteosarcoma of the jaws in children are reported.
  • She was found to have chondroblastic osteosarcoma extending through the left maxillary alveolar process and sinus.
  • Following surgery and chemotherapy, the patient has been free of disease for 7 years.
  • The second patient, an 8-year-old boy, was diagnosed with juxtacortical (parosteal) osteosarcoma of the mandible, which is a less aggressive variant of the neoplasm.
  • It is believed that this is the youngest patient reported to date with juxtacortical osteosarcoma of the jaws.
  • He was treated by block resection of the right side of the mandible and is free of disease 3(1/2) years later.

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14706029.001).
  • [ISSN] 0960-7439
  • [Journal-full-title] International journal of paediatric dentistry
  • [ISO-abbreviation] Int J Paediatr Dent
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Benjamin RS, Patel SR: Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res; 2009;152:355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy.
  • Most data on osteosarcoma is derived from pediatric studies.
  • Although the majority of adult patients with osteosarcoma are young adults, who might be treated in a similar fashion, experience derived from a slightly older population is helpful in directing therapy.
  • We treated a series of 123 patients with osteosarcoma of the extremities with adriamycin and cisplatin as induction therapy.
  • Sequential addition of methotrexate and methotrexate plus ifosfamide in subsequent cohorts improved the continuous relapse-free survival of poor responders such that overall survival improvement was noted in the group where therapy was modified by adding both agents to those with <90% tumor necrosis.
  • Patients with chondroblastic osteosarcoma with poor necrosis had a trend towards improved continuous relapse-free survival compared with other patients with conventional osteosarcoma.
  • Histologic variants of osteosarcoma except telangiectatic osteosarcoma had a worse prognosis than those with conventional osteosarcoma.
  • The variants, especially dedifferentiated parosteal osteosarcoma and dedifferentiated well-differentiated intraosseous osteosarcoma are more common in adults than children, accounting for some of the inferior prognosis in adults.
  • Older patients obviously cannot tolerate the doses of therapy given to children and young adults, again decreasing the chances of successful treatment.
  • Patients with secondary osteosarcoma are often much older as are many with osteosarcomas of the pelvis and jaw.
  • These tumors tend to be less responsive.
  • An attempt to intensify therapy in poor-prognosis patients with a three-drug regimen of adriamycin, cisplatin, and ifosfamide with peripheral stem cell support was unsuccessful at prolonging relapse-free survival, and we no longer use that approach.
  • [MeSH-major] Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213401.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


15. Azura M, Vanel D, Alberghini M, Picci P, Staals E, Mercuri M: Parosteal osteosarcoma dedifferentiating into telangiectatic osteosarcoma: importance of lytic changes and fluid cavities at imaging. Skeletal Radiol; 2009 Jul;38(7):685-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parosteal osteosarcoma dedifferentiating into telangiectatic osteosarcoma: importance of lytic changes and fluid cavities at imaging.
  • PURPOSE: This study was performed to assess the imaging findings in cases of parosteal osteosarcoma dedifferentiated into telangiectatic osteosarcoma.
  • Parosteal osteosarcoma is a low-grade well-differentiated malignant tumor.
  • Only one case of differentiation into a telangiectatic osteosarcoma has been reported.
  • As it has practical consequences, with a need for aggressive chemotherapy, we looked for this rather typical imaging pattern.
  • MATERIALS AND METHODS: Review of 199 cases of surface osteosarcomas (including 86 parosteal, of which 23 were dedifferentiated) revealed lesions suggesting a possible telangiectatic osteosarcoma on imaging examinations in five cases (cavities with fluid).
  • Histology confirmed three cases (the two other only had hematoma inside a dedifferentiated tumor).
  • RESULTS: Lesions involved the distal femur, proximal tibia, and proximal humerus.
  • The parosteal osteosarcoma was a sclerotic, regular mass, attached to the cortex.
  • It involved the medullary cavity twice, and remained outside the bone once.
  • CONCLUSION: Knowledge of this highly suggestive pattern should help guide the initial biopsy to diagnose the two components of the tumor, and guide aggressive treatment.
  • [MeSH-major] Bone Neoplasms / diagnostic imaging. Femoral Neoplasms / diagnostic imaging. Osteosarcoma / classification. Osteosarcoma / diagnostic imaging. Telangiectasis / diagnostic imaging
  • [MeSH-minor] Adult. Cell Differentiation. Humans. Male. Tomography, X-Ray Computed. Young Adult

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Skeletal Radiol. 2010 Jan;39(1):69; author reply 71 [19826810.001]
  • [Cites] Cancer. 1976 May;37(5):2466-75 [1063060.001]
  • [Cites] J Bone Joint Surg Am. 1985 Jul;67(6):901-10 [3860505.001]
  • [Cites] J Bone Joint Surg Am. 1994 Mar;76(3):366-78 [8126042.001]
  • [Cites] Clin Orthop Relat Res. 1991 Sep;(270):135-9 [1884532.001]
  • [Cites] Cancer. 2005 Jun 1;103(11):2373-82 [15852358.001]
  • [Cites] J Bone Joint Surg Br. 1984 May;66(3):313-21 [6586725.001]
  • [Cites] Ann Surg. 1951 Jun;133(6):790-807 [14838523.001]
  • [Cites] Skeletal Radiol. 2000 Oct;29(10):597-600 [11127684.001]
  • [Cites] Cancer. 1996 Nov 15;78(10):2136-45 [8918422.001]
  • (PMID = 19271217.001).
  • [ISSN] 1432-2161
  • [Journal-full-title] Skeletal radiology
  • [ISO-abbreviation] Skeletal Radiol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


16. Samardziski M, Zafiroski G, Tolevska C, Konstadinova-Kunovska S, Vasilevska V: Parosteal osteosarcoma. Bratisl Lek Listy; 2009;110(4):240-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parosteal osteosarcoma.
  • In this retrospective clinical study, 6 cases of osteosarcoma of the bone have been analyzed.
  • Five patients were with parosteal osteosarcoma and one with periosteal osteosarcoma.
  • This tumor represents 1.5% of all primary bone tumors treated at the Clinic in the 11 year period.
  • The history analysis of the patients showed misinterpreted diagnosis in 50% of the cases, with 83.3% rate of local recurrence, 33.3% of metastases and 33.3% of mortality.
  • The clinical and histopathological findings (identical with those reviewed in the literature) confirmed occurrence of two biologically different types of parosteal osteosarcoma: predominant type is originally "benign" but has a definite malignant potential, causing metastases after long symptom-free interval.
  • The other type is highly malignant from the beginning.
  • More radical surgery is recommended for the latter category of tumors, followed by chemotherapy.
  • Compartmental, radical "en bloc" resection, followed by regular review of the patients, is recommended for the former (Tab. 1, Fig.
  • [MeSH-major] Bone Neoplasms / diagnosis. Osteosarcoma, Juxtacortical / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Female. Femoral Neoplasms / diagnosis. Humans. Humerus. Male. Tibia. Young Adult


17. Rodríguez-Arias CA, Lobato RD, Millán JM, Lagares A, de la Lama A, Alén JF: Parosteal osteosarcoma of the skull. Neurocirugia (Astur); 2001 Dec;12(6):521-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Parosteal osteosarcoma of the skull.
  • Parosteal osteosarcoma of the skull is a distinct surface bone tumor, with a better prognosis than conventional osteosarcoma.
  • The most common location is on the surface of the distal femur which accounts for 46-66% of the cases.
  • We describe the case of a man who developed a parosteal osteosarcoma arising from the occipital bone with extension to the parietal bone.
  • The patient was operated and had a complete tumor resection.
  • [MeSH-major] Occipital Bone / pathology. Osteosarcoma, Juxtacortical / pathology. Parietal Bone / pathology. Skull Neoplasms / pathology
  • [MeSH-minor] Cerebral Angiography. Chemotherapy, Adjuvant. Combined Modality Therapy. Craniotomy. Diagnosis, Differential. Disease Progression. Fatal Outcome. Humans. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Neoplasm Recurrence, Local / surgery. Osteosarcoma / diagnosis. Osteosarcoma / drug therapy. Osteosarcoma / pathology. Osteosarcoma / radiotherapy. Osteosarcoma / secondary. Radiotherapy, Adjuvant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Osteosarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11787402.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 16
  •  go-up   go-down


18. Goto T, Okuma T, Ogura K, Imanishi J, Hozumi T, Kondo T: [Indication of chemotherapy according to histological type of musculoskeletal sarcomas]. Gan To Kagaku Ryoho; 2009 Feb;36(2):199-203
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Indication of chemotherapy according to histological type of musculoskeletal sarcomas].
  • In high-grade musculoskeletal sarcomas, adjuvant chemotherapy is often performed to prevent distant metastases.
  • As the efficacy of chemotherapy varies according to the histological type of sarcoma, its indication is determined according to the histological type and the stage.
  • Prognoses are poor in patients with osteosarcoma, Ewing's sarcoma, or rhabdomyosarcoma, when surgery alone is performed.
  • However, because these sarcomas are chemosensitive, their prognoses are improved with adjuvant chemotherapy, so it is absolutely necessary.
  • Drugs commonly used for osteosarcoma include adriamycin, cisplatin, methotrexate, vincristine, and ifosfamide.
  • For Ewing's sarcoma and rhabdomyosarcoma, vincristine, actinomycin-D, cyclophosphamide, etoposide, and ifosfamide are commonly used.
  • On the other hand, the efficacy of chemotherapy is unclear in most of the non-round cell sarcomas, e. g., malignant fibrous histiocytoma, pleomorphic liposarcoma, and leiomyosarcoma, so adjuvant chemotherapy is relatively indicated and often performed preoperatively.
  • The efficacy is evaluated by reduction of the tumor volume as a surrogate marker.
  • Postoperative chemotherapy is performed when the preoperative chemotherapy is effective.
  • Nowadays, several kinds of antitumor agents are usually used for non-round cell sarcomas, and many authors have reported various kinds of regimens and their clinical results.
  • Among them, the key drugs are adriamycin and ifosfamide.
  • For chemoresistant sarcomas, e. g., chondrosarcoma, chordoma, alveolar soft part sarcoma, chemotherapy is rarely indicated, even if the tumor is histologically high grade and large.
  • Low-grade musculoskeletal sarcomas, e. g., low-grade chondrosarcoma, central low-grade osteosarcoma, parosteal osteosarcoma, well-differentiated liposarcoma, and dermatofibrosarcoma protuberans, are well cured only by surgical excision, and adjuvant chemotherapy is therefore not indicated.
  • Superficially-located, small-size non-round cell sarcomas, even though histologically high grade, are well healed only by surgical excision, and adjuvant chemotherapy is rarely indicated.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Musculoskeletal Diseases / drug therapy. Musculoskeletal Diseases / pathology. Neoplasms, Muscle Tissue / drug therapy. Neoplasms, Muscle Tissue / pathology. Sarcoma / drug therapy. Sarcoma / pathology
  • [MeSH-minor] Combined Modality Therapy. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19223736.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


19. El Ajmi M, Ksantini R, Chebbi F, Makni A, Rebai W, Daghfous A, Bedioui H, Fteriche F, Jouini M, Kacem M, Ben Safta Z: Abdominal metastasis of a parosteal osteosarcoma of the femur: an unusual cause of large-bowel obstruction. Acta Chir Belg; 2009 Oct;109(5):633-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal metastasis of a parosteal osteosarcoma of the femur: an unusual cause of large-bowel obstruction.
  • BACKGROUND: Parosteal osteosarcoma is a rare, well-differentiated, predominantly fibro-osseous variant of osteosarcoma.
  • It is regarded as a distinct form of osteosarcoma with better prognosis than conventional osteosarcoma.
  • AIM: We report an unusual case of abdominal mass recurrence of parosteal osteosarcoma of the left distal femur treated eight years previously with wide resection, hip disarticulation and chemotherapy, which presented as an acute abdomen: we discuss the clinical outcomes of this rare entity.
  • CASE PRESENTATION: We present a 54-year-old patient with low-grade parosteal osteosarcoma of the left distal femur.
  • Left total hip disarticulation was indicated after several local relapses of the tumour following extensive resection and chemotherapy.
  • Abdominal computed tomography showed a large abdominal calcified mass with dilated large bowel loops.
  • Biopsy of the lesion yielded grade III parosteal osteosarcoma material.
  • The patient received adjuvant chemotherapy, but the response was poor: six months later, the patient presented with a peristomal mass and two pulmonary metastases.
  • CONCLUSION: Abdominal recurrence of parosteal osteosarcoma of the distal femur eight years after definitive surgery is rare.
  • This case emphasises the importance of the long-term follow-up of patients with parosteal osteosarcoma.
  • [MeSH-major] Colonic Neoplasms / secondary. Femoral Neoplasms / pathology. Intestinal Obstruction / etiology. Osteosarcoma / secondary
  • [MeSH-minor] Colostomy. Female. Humans. Lung Neoplasms / secondary. Middle Aged. Tomography, X-Ray Computed


20. Tang X, Guo W, Yang R: [Segmental allograft reconstruction in skeletal defect after limb tumor resection]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi; 2006 Oct;20(10):985-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Segmental allograft reconstruction in skeletal defect after limb tumor resection].
  • OBJECTIVE: To study the clinical feasibility of the prosthetic composites of the intercalary allograft and the segmental allograft in reconstruction of the skeletal defect after the limb tumor resection.
  • METHODS: Between August 1999 and December 2003, 28 patients with skeletal defects after the limb tumor resection were treated with the intercalary allograft or the segmental allograft megaprosthesis composite for reconstruction of skeletal defects.
  • The bone involvements were observed in 16 patients with osteosarcoma, 4 patients with parosteal osteosarcoma, 5 patients with Ewing sarcoma, and 3 patients with soft tissue sarcoma.
  • The patients with osteosarcoma or Ewing sarcoma received the standard chemotherapy before and after operation.
  • Of the 28 patients, 3 developed nonunion of the allograft-host junction accompanied by severe resorption and 2 developed deep infection.
  • CONCLUSION: The prosthetic composite replacement of the intercalary allograft and the segmental allograft can be used in the skeletal defect reconstruction after the limb tumor resection.
  • [MeSH-major] Bone Neoplasms. Bone Transplantation. Osteosarcoma. Reconstructive Surgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Grafts.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140069.001).
  • [ISSN] 1002-1892
  • [Journal-full-title] Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgery
  • [ISO-abbreviation] Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement